JPH0235081A - アルギニン・デイミナーゼおよびその用途 - Google Patents

アルギニン・デイミナーゼおよびその用途

Info

Publication number
JPH0235081A
JPH0235081A JP63184556A JP18455688A JPH0235081A JP H0235081 A JPH0235081 A JP H0235081A JP 63184556 A JP63184556 A JP 63184556A JP 18455688 A JP18455688 A JP 18455688A JP H0235081 A JPH0235081 A JP H0235081A
Authority
JP
Japan
Prior art keywords
arginine
arginine deiminase
deiminase
enzyme
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP63184556A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0331436B2 (https=
Inventor
Yutaka Sato
裕 佐藤
Junji Kobayashi
準次 小林
Kazuo Houriyou
一生 芳陵
Makoto Nogawa
野川　誠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institute of Advanced Industrial Science and Technology AIST
Original Assignee
Agency of Industrial Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency of Industrial Science and Technology filed Critical Agency of Industrial Science and Technology
Priority to JP63184556A priority Critical patent/JPH0235081A/ja
Publication of JPH0235081A publication Critical patent/JPH0235081A/ja
Publication of JPH0331436B2 publication Critical patent/JPH0331436B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP63184556A 1988-07-26 1988-07-26 アルギニン・デイミナーゼおよびその用途 Granted JPH0235081A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP63184556A JPH0235081A (ja) 1988-07-26 1988-07-26 アルギニン・デイミナーゼおよびその用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63184556A JPH0235081A (ja) 1988-07-26 1988-07-26 アルギニン・デイミナーゼおよびその用途

Publications (2)

Publication Number Publication Date
JPH0235081A true JPH0235081A (ja) 1990-02-05
JPH0331436B2 JPH0331436B2 (https=) 1991-05-07

Family

ID=16155274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63184556A Granted JPH0235081A (ja) 1988-07-26 1988-07-26 アルギニン・デイミナーゼおよびその用途

Country Status (1)

Country Link
JP (1) JPH0235081A (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024473A1 (fr) * 1996-12-03 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de fibrose des tissus
US9125876B2 (en) 2005-04-25 2015-09-08 Erytech Pharma Erythrocytes containing arginine deiminase
US9364504B2 (en) 2007-08-08 2016-06-14 Erytech Pharma Compostition and therapeutic anti-tumour vaccine
EP3449935A1 (en) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY
US12201652B2 (en) 2016-05-03 2025-01-21 Stemcell Technologies Canada Inc. Intracellular delivery of biomolecules to induce tolerance

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998024473A1 (fr) * 1996-12-03 1998-06-11 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de fibrose des tissus
US9125876B2 (en) 2005-04-25 2015-09-08 Erytech Pharma Erythrocytes containing arginine deiminase
US9364504B2 (en) 2007-08-08 2016-06-14 Erytech Pharma Compostition and therapeutic anti-tumour vaccine
US9950049B2 (en) 2007-08-08 2018-04-24 Erytech Pharma Composition and therapeutic anti-tumour vaccine
US10780151B2 (en) 2007-08-08 2020-09-22 Erytech Pharma Composition and therapeutic anti-tumour vaccine
US12201652B2 (en) 2016-05-03 2025-01-21 Stemcell Technologies Canada Inc. Intracellular delivery of biomolecules to induce tolerance
EP3449935A1 (en) 2017-08-31 2019-03-06 Erytech Pharma Arginine deiminase encapsulated inside erythrocytes and their use in treating cancer and arginase-1 deficiency
WO2019042628A1 (en) 2017-08-31 2019-03-07 Erytech Pharma ARGININE DEIMINASE ENCAPSULATED WITHIN ERYTHROCYTES AND THEIR USE IN THE TREATMENT OF CANCER AND ARGINASE-1 DEFICIENCY

Also Published As

Publication number Publication date
JPH0331436B2 (https=) 1991-05-07

Similar Documents

Publication Publication Date Title
Broome Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects: I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance
Elsbach et al. Separation and purification of a potent bactericidal/permeability-increasing protein and a closely associated phospholipase A2 from rabbit polymorphonuclear leukocytes. Observations on their relationship.
US4245051A (en) Human serum plasminogen activator
EP0156169B1 (en) An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
EP0100982B1 (en) Novel purified plasminogen activator, process for its production and thrombolytic composition containing it
Grundmann et al. Experimental and Clinical Effects of L-Asparaginase: International Symposium of Experimtal and Clinical Effects of L-Asparaginase, Wuppertal-Elberfeld 1969
JPH0235081A (ja) アルギニン・デイミナーゼおよびその用途
Persidsky et al. Optimal conditions and comparative effectiveness of dimethyl sulphoxide and polyvinylpyrrolidone in preservation of bone marrow
Ogburn et al. Extracellular antigens in steady-state cultures of the hemolytic streptococcus: production of proteinase at low pH
EP0248656B1 (en) Composition for cell cultivation and use thereof
EP0104194B1 (en) New fibrinolytic enzymes, methods for their production and pharmaceutical compositions containing them
Poste Production of a serine-protease with macrophage migration-inhibitory factor activity by virus-transformed cells and human tumor cell lines
EP0149751A2 (en) Proteinaceous substance showing antitumorous action and method for its manufacture
CN110760494A (zh) 一种单环刺螠自溶酶的制备及应用
Satoshi et al. Analysis of non-heme iron in arachidonate 12-lipoxygenase of porcine leukocytes
Westfall et al. The arginase and rhodanese activities of certain cell strains after long cultivation in vitro
JPS63126897A (ja) 免疫抑制因子
Clark et al. Extracellular amino acid effects on milk and intracellular amino acid pools with bovine mammary cells in culture
EP0151996A2 (en) Process for the Preparation of a double-chain plasminogen activator
JPS60181028A (ja) 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助法
Rugstad Purification of a kinin-inactivating enzyme from cultures of Pseudomonas aeruginosa
JPH04295500A (ja) 新規な巨核球増幅因子とその製法
Ralph Continuous cell lines with properties of mononuclear phagocytes
AU630873B2 (en) Lung growth stimulatory and inhibitory factors for carcinoma tumor cells
JD Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance.

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term